| Teva Pharmaceutical Industries Ltd. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120095264 | SOLID STATES OF ALISKIREN FREE BASE - The present invention describes a solid state of aliskiren free base, and process for the preparation thereof. | 04-19-2012 |
| 20120003249 | IMMUNO-MOLECULES CONTAINING VIRAL PROTEINS, COMPOSITIONS THEREOF AND METHODS OF USING - An immuno-molecule which comprises a soluble human MHC class I effector domain; and an antibody targeting domain which is linked to the soluble human MHC class I effector domain, methods of making same and uses thereof. | 01-05-2012 |
| 20110150874 | FUSION PROTEINS, USES THEREOF AND PROCESSES FOR PRODUCING SAME - This invention provides fusion proteins comprising consecutive amino acids which beginning at the amino terminus of the protein correspond to consecutive amino acids present in (i) a cytomegalovirus human MHC-restricted peptide, (ii) a first peptide linker, (iii) a human β-2 microglobulin, (iv) a second peptide linker, (v) a HLA-A2 chain of a human MHC class I molecule, (vi) a third peptide linker, (vii) a variable region from a heavy chain of a scFv fragment of an antibody, and (viii) a variable region from a light chain of such scFv fragment, wherein the consecutive amino acids which correspond to (vii) and (viii) are bound together directly by a peptide bond or by consecutive amino acids which correspond to a fourth peptide linker, wherein the antibody from which the scFv fragment is derived specifically binds to mesothelin. This invention provides nucleic acid constructs encoding same, processes for producing same, compositions, and uses thereof. | 06-23-2011 |
| 20110118477 | SUNITINIB AND SALTS THEREOF AND THEIR POLYMORPHS - Process for the preparation of sunitinib malate form I via sunitinib acetate and polymorphs of said intermediate. | 05-19-2011 |
| 20110086102 | DELAYED RELEASE COMPOSITIONS - The present invention provides delayed release pharmaceutical compositions comprising an active pharmaceutical ingredient, e.g. mycophenolate sodium, and an enteric polymer, and methods for preparing the same. Preferably, the pharmaceutical compositions do not contain a coating. | 04-14-2011 |
| 20100317702 | CRYSTALLINE FORM OF FEBUXOSTAT - New forms of Febuxostat have been prepared and characterized. These forms are useful, for example, in the chronic management of hyperuricemia in patients with gout. | 12-16-2010 |
| 20100249140 | SOLID STATE FORMS OF SITAGLIPTIN SALTS - Solid state forms of Sitagliptin salts, processes for preparing the solid state forms, and pharmaceutical compositions thereof, are provided. | 09-30-2010 |
| 20100216831 | DESLORATADINE CRYSTALLINE FORMS MIXTURES HAVING A LOW LEVEL OF RESIDUAL SOLVENTS - Provided are desloratadine mixtures, comprising a low level of residual solvents and processes for the preparation thereof. | 08-26-2010 |
| 20100190812 | NILOTINIB HCL CRYSTALLINE FORMS - Crystalline forms of Nilotinib HCl are described. | 07-29-2010 |
| 20100189878 | PROCESSES FOR COATING A CARRIER WITH MICROPARTICLES - Processes for coating a carrier with microparticles of a drug are described. For example, a coated carrier can be obtained in a one-stage process that entails evaporating a solvent from microdroplets of a solution containing an API to obtain dry microparticles, which are then coated on the carrier. | 07-29-2010 |
| 20100168247 | SOLID COMPOSITES OF A CALCIUM RECEPTOR-ACTIVE COMPOUND - The invention encompasses solid composites of the calcium receptor-active compounds, processes for preparing the solid composites, immediate and controlled-release pharmaceutical formulations comprising the solid composites, and methods of treatment therewith. | 07-01-2010 |
| 20100160666 | PREPARATION OF GABAPENTIN ENACARBIL INTERMEDIATE - Allyl 1 {[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetate can be prepared by combining allyl 1-aminomethyl-1-cyclohexane acetate hydrochloride, a polar organic solvent, chloroethyl chloroformate, and an amine base or an inorganic base selected from a group consisting of carbonate and bicarbonate to provide a reaction mixture; and adding isobutyric acid to the reaction mixture. The product can be purified and/or converted to gabapentin enacarbil. | 06-24-2010 |
| 20100160665 | PROCESSES FOR THE PREPARATION AND PURIFICATION OF GABAPENTIN ENACARBIL - Gabapentin enacarbil was prepared and purified from intermediates such as 1-haloalkyl carbamate or carbonate and diacid acetal skeleton. For example, a 1-haloalkyl carbonate or carbamate was prepared by combining a C | 06-24-2010 |
| 20100160646 | PROCESSES FOR PREPARING SUNITINIB AND SALTS THEREOF - Methods for preparing sunitinib or salts thereof are described using novel intermediates and chemical pathways. One such intermediate is: | 06-24-2010 |
| 20100158959 | Stable Combinations of Amlodipine Besylate and Benazepril Hydrochloride - The present invention provides a pharmaceutical composition comprising benazepril and amlodipine wherein the benazepril and the amlodipine are in physical contact with one another, and methods for making the same. | 06-24-2010 |
| 20100099687 | TADALAFIL SOLID COMPOSITES - This invention relates to oral pharmaceutical compositions suitable for making pharmaceutical formulations for oral administration that provide for the rapid dissolution of the phosphodiesterase 5 inhibitor tadalafil. In particular, the pharmaceutical compositions comprise solid composites of tadalafil exhibiting high solubility and rate of dissolution. The invention further relates to methods of preparing these pharmaceutical formulations and the use of such pharmaceutical formulations for treating diseases associated with PDE5 inhibitors. | 04-22-2010 |
| 20100076195 | PURIFICATION OF MONTELUKAST - The present invention provides methods of purifying montelukast, a new isolated impurity of montelukast, method for its isolation, and method of using montelukast impurity as a reference marker and a reference standard. | 03-25-2010 |
| 20100056583 | Polymorphic forms of rosiglitazone hydrobromide and processes for their preparation - The present invention provides crystalline forms of Rosiglitazone hydrobromide, methods of their preparation, as well as pharmaceutical compositions comprising these crystalline forms. | 03-04-2010 |
| 20100029943 | METHODS FOR PREPARING ESZOPICLONE CRYSTALLINE FORM A, SUBSTANTIALLY PURE ESZOPICLONE AND OPTICALLY ENRICHED ESZOPICLONE - The present invention provides methods for preparing eszopiclone Form A, substantially chemically pure eszopiclone, or eszopiclone with low level(s) of residual solvent(s). The present invention also provides eszopiclone with low level(s) of residual solvent(s). The present invention also provides a process for optical enrichment of eszopiclone free base. For instance, one of the embodiments of the invention is directed to a method of preparing eszopiclone Form A, wherein the method comprises crystallizing eszopiclone free base from a solvent selected from the group consisting of isopropanol (IPA), methyl isobutyl ketone (MIBK), acetone, n-butanol, i-butanolisobutanol, 2-butanol, tetrahydrofuran (THF), dimethyl carbonate, methanol, ethanol, ethyl lactate, dimethylformamide (DMF), carbon tetrachloride, toluene, iso-butyl acetate and mixtures thereof. | 02-04-2010 |
| 20100016590 | NILOTINIB INTERMEDIATES AND PREPARATION THEREOF - Intermediates of Nilotinib were prepared, including, for example, 3-(trifluoromethyl-5-(4-methyl-1H-imidazole-1-yl)-benzeneamine; 3-(4-(pyridin-3-yl)pyrimidin-2-ylamino) -4-methylbenzoyl halogen dihydrochloride; and N-(3-Bromo-5-trifluoromethylphenyl)-4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzamide. Nilotinib.3HCl and its crystalline forms are also described. | 01-21-2010 |
| 20100004485 | GABAPENTIN ENACARBIL SALTS AND PROCESSES FOR THEIR PREPARATION - The preparation and use of calcium, barium, magnesium and copper salts of gabapentin enacarbil are described. | 01-07-2010 |
| 20090318728 | PROCESSES FOR PREPARING PRODRUGS OF GABAPENTIN AND INTERMEDIATES THEREOF - Gabapentin prodrugs and intermediates thereof are described. | 12-24-2009 |
| 20090311322 | ATORVASTATIN FORMULATION - Provided are atorvastatin compositions which reduce the effect of food on the bioavailability of atorvastatin and methods for making such compositions. Also provided are methods of reducing low density lipoprotein by administering the compositions of the invention. | 12-17-2009 |
| 20090292025 | Novel crystalline forms of armodafinil and preparation thereof - The invention encompasses crystalline forms of armodafinil, processes for preparing the crystalline forms, and pharmaceutical formulation. | 11-26-2009 |
| 20090247767 | PROCESSES FOR PREPARING SUNITINIB AND SALTS THEREOF - Methods for preparing sunitinib or salts thereof are described using novel intermediates and chemical pathways. One such intermediate is: | 10-01-2009 |
| 20090240054 | Rosuvastatin calcium with a low salt content - Provided is rosuvastatin calcium with a low salt by product content and processes for preparing such rosuvastatin calcium. | 09-24-2009 |
| 20090188305 | Reference standard for characterization of rosuvastatin - Provided are rosuvastatin degradation products and their use as a reference standard (including reference marker) for analysis of rosuvastatin. | 07-30-2009 |
| 20090082398 | CRYSTALLINE FORMS OF FEXOFENADINE HYDROCHLORIDE AND PROCESSES FOR THEIR PREPARATION - Provided are crystalline forms of fexofenadine hydrochloride and processes for their preparation. | 03-26-2009 |
| 20080319191 | Crystalline form IV of linezolid - The present invention provides a novel crystalline form of linezolid referred to herein as Form IV as well as methods for the preparation and use of Form IV. The present invention provides pharmaceutical compositions that comprise therapeutically effective amounts of Form IV that can be used to treat patients suffering from gram-positive bacterial infections. Various processes for making crystalline linezolid Form IV are disclosed. | 12-25-2008 |
| 20080269505 | Processes for preparing darifenacin hydrobromide - The invention encompasses processes for the preparation of darifenacin hydrobromide. | 10-30-2008 |
| 20080269504 | Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof - Provided are darifenacin hydrobromide free of oxidized darifenacin, and processes for the preparation thereof. | 10-30-2008 |
| 20080269503 | Processes for preparing darifenacin hydrobromide - The invention encompasses processes for the preparation of darifenacin hydrobromide. | 10-30-2008 |
| 20080269202 | Novel 2,3-benzodiazepine derivatives and their use as antipsychotic agents - Disclosed are novel 2,3-benzodiazepine derivatives and methods of making the same. | 10-30-2008 |
| 20080200720 | PROCESS FOR THE SYNTHESIS OF ENANTIOMERIC INDANYLAMINE DERIVATIVES - A process for manufacturing (R)-propynylaminoindans, and alternatively, a process for manufacturing (S)-propynylaminoindans. The chiral propynylaminoindans include alkoxy or alkylcarbamates derivatives. The process comprises transfer or pressure hydrogenation in the presence of an optically active catalyst to reduce 1-indanones. The chiral product, either (S)- or (R)-indanols undergo nucleophilic substitution to produce the named product. In an additional aspect, the invention relates to novel intermediates and compounds, namely, substituted indanones, substituted (S)-indanols and substituted (R)-indanols. | 08-21-2008 |
